Search results
Added:
4 weeks ago
ESC HF 25 - Secondary analysis of the FINEARTS-HF study shows finerenone treatment favourably influenced the risk of early heart failure readmission.Dr Ankeet Bhatt (Kaiser Permanante San Francisco Medical Center, San Francisco, US) discusses findings from the prespecified secondary analysis of the FINEARTS-HF trial (NCT04435626; Bayer). The placebo-controlled primary analysis investigated the…
View more
Added:
8 months ago
EASD 24 - We are joined by Dr Helen Coulhoun (University of Edinburgh, UK) to discuss the key findings of a prespecified analysis of the SELECT trial, which investigated the effectiveness of semaglutide in reducing major cardiac events in the presence of impaired kidney function in patients with overweight and obesity.Findings showed that participants in the study with reduced eGFR and/or…
View more
Added:
1 year ago
HFA 24 - We are joined by Dr Jasper J Brugts (Erasmus University Medical Centre, NL) to discuss the findings of a predefined subgroup analysis of the MONITOR-HF study (NTR7672).MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherlands. Eligible patients had chronic heart failure of New York Heart Association class III and a previous heart failure hospitalisation,…
View more
Added:
4 weeks ago
ESC HF 25 - A secondary analysis of TIM-HF2 showed that patients residing farther from their cardiologist benefited further from remote patient management (RPM).Prof Stefan Störk (University Hospital Wuerzburg, DE) discusses the findings from a pre-specified, secondary analysis of TIM-HF2, investigating the impact of rurality and travel distance on the effectiveness of RPM in patients…
View more
Added:
9 months ago
EASD 24 - We are joined by Professor John McMurray (University of Glasgow, UK) to discuss the key findings from a diabetes subgroup analysis of the FINEARTS-HF study.Interview Questions:1. What is the reasoning behind this analysis?2. What was the study design and patient cohort?3. What are the key findings?4. In your opinion, what can explain this risk reduction?5. What are the take-home…
View more
Added:
1 year ago
AHA 23 — Dr Hanad Bashir, CardioNerds ambassador, interviews Prof William T Abraham (The Ohio State University, US) on the findings of a clinical evaluation of the Cordio app in adult patients with acute decompensated heart failure.The Cordio "HearO" app (Cordio Medical) uses patient speech sampled via mobile phone to sense fluid accumulation related to chronic heart failure, and provides alerts…
View more
Added:
1 year ago
AHA 23 - We are joined on-site by Prof Uwe Zeymer (Klinikum Ludwigshafen, Ludwigshafen, DE) to discuss the findings from a sub-analysis of the ECLS-SHOCK trial.This sub-analysis investigates the impact of cardiac arrest before randomisation on the efficacy of ECLS in patients with infarct-related cardiogenic shock. Investigators enrolled 420 patients with acute MI and cardiogenic shock across 41…
View more
Added:
1 year ago
ACC.24 — Dr Andrew P DeFilipis (Vanderbilt University Medical Center, US) joins us onsite at ACC to discuss the findings from a subgroup analysis of the MINT Trial (NCT02981407).MINT is a randomised parallel assignment trial which aims to compare liberal and restrictive blood cell transfusion strategies in patients who have had an acute myocardial infarction (AMI) and are anaemic. Findings were…
View more
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: Brad WilsonIn a study published in the Journal of the American College of Cardiology (JACC), Dr Elias Björnson and his colleagues demonstrated that lipoprotein(a) (Lp(a)) is approximately six times more atherogenic than low-density lipoprotein (LDL) per particle.Lp(a) is a lipoprotein particle that has long been recognised as a causal factor for coronary heart disease (CHD). However,…
View more
New Insights on HFpEF Treatment
Added:
1 year ago
Article
